For families touched by Frontotemporal Lobar Degeneration (FTLD), or any disease that has no cure, a cure can’t be found soon enough.
At our recent FTLD Caregiver Conference, we caught up with Murray Grossman, MD, EdD, director of the Penn FTLD Center, to ask him about the progress in FTLD research. His comments during the conference were very promising, saying that “we’re on the cusp of disease-modifying drugs,” for frontotemporal lobar degeneration, with a goal of having a treatment for FTLD in 10 years.
In this video, Dr. Grossman explains the latest biological understanding of the disease, improvements in diagnostic tools, and efforts towards finding treatments that modify or stop the progression of FTLD and related diseases.
If you’re interested in clinical trial information for FTLD, visit the Penn FTLD Center website, or check back here for updates.